Postoperative antithrombotic therapy after coronary artery bypass grafting combined with coronary endarterectomy (PATH-CARE): study protocol for a randomised controlled clinical trial.

ABSTRACT:

Introduction

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) has been associated with poor graft patency, which might be attributed to the activation of coagulation cascade caused by the exposure of the subendothelial tissue to the blood stream, which could necessitate anticoagulation therapy. However, the optimal antithrombotic therapy after CE+CABG remains unclear.

Methods and analysis

The PATH-CARE is a double-centre, two-armed, blinded to outcome assessed, randomised controlled trial, aimed to determine the optimal antithrombotic therapy after CE+CABG. A total of 202 patients are expected to be recruited. Patients will be randomly assigned in a 1:1 ratio to the control (dual antiplatelet therapy (AT) group) and the intervention (dual AT+

SUBMITTER: Tiemuerniyazi X 

PROVIDER: S-EPMC12598976 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature